readthroughSign in
Nov 16, 2026Trial update

Biogen registers Phase 2 trial of felzartamab (BIIB148) in generalized myasthenia gravis

Biogen has registered a Phase 2 study, MYAMERGE, testing felzartamab against placebo in adults with generalized myasthenia gravis, not yet recruiting.

This week brought a single new registry record for Biogen.

  • Biogen registered "A Phase 2 Multicenter Study Evaluating the Efficacy and Safety of Felzartamab Compared to Placebo in Adults With Generalized Myasthenia Gravis" (NCT07939802, acronym MYAMERGE), listed as a Phase 2 multicenter study evaluating felzartamab, also known as BIIB148, against placebo in adult participants with generalized myasthenia gravis.1 The study is not yet recruiting, with an estimated start of 2026-11-19 and estimated enrollment of 75 participants, and the main question is whether felzartamab increases the ability to perform daily activities after 26 weeks of treatment in participants with AChR antibodies.1

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.